ProQR Therapeutics (PRQR) announced the appointment of Dennis Hom as Chief Financial Officer, CFO, and Cristina Lopez Lopez, MD, PhD, as Chief Medical Officer, CMO. These key leadership appointments support the advancement of the Company’s Axiomer platform technology and pipeline of RNA editing programs as it enters the clinical stage.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PRQR:
- ProQR Therapeutics Advances RNA Editing Pipeline
- ProQR’s Axiomer Technology and AX-0810: A Promising Buy Rating with Increased Price Target
- ProQR Therapeutics price target raised to $12 from $10 at H.C. Wainwright
- ProQR Therapeutics files to sell 3.52M ordinary shares for holders
- ProQR Therapeutics Reports 2024 Results and Pipeline Progress